Opinion for the Court filed PER CURIAM.
On Motion for Summary Affirmance
PER CURIAM.
This case is the latest flare-up in a long-running dispute between the Food and Drug Administration (FDA) and several generic drug manufacturers as to what qualifies under the Hatch-Waxman Act as "a decision of a court . . . holding [a challenged] patent . . . to be invalid or not infringed." 21 U.S.C. § 355(j)(5)(B)(iv) (2000) (amended 2003). The stakes are...
Let's get started
Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.
- Updated daily.
- Uncompromising quality.
- Complete, Accurate, Current.